Trevi Therapeutics (TRVI) Current Leases (2019 - 2026)
Trevi Therapeutics (TRVI) posted quarterly Current Leases of $318000.0 for Q1 2026, up 15.22% year-over-year from $276000.0 in Q1 2025, and up 3.58% quarter-over-quarter from $307000.0 in Q4 2025.
Powered by 
Analysis
Trevi Therapeutics (TRVI) Current Leases (2019 - 2026) Analysis & Trends
Trevi Therapeutics' Current Leases history runs 8 years deep, the most recent figure standing at $318000.0 for Q1 2026.
- In Q1 2026, Current Leases rose 15.22% year-over-year to $318000.0; the TTM figure through Mar 2026 stood at $318000.0 (up 15.22% YoY), while the FY2025 annual figure was $307000.0, up 890.32% from the prior year.
- Current Leases for Q1 2026 stood at $318000.0, up from $307000.0 in the prior quarter.
- The five-year high for Current Leases was $318000.0 in Q1 2026, with the low at $25000.0 in Q4 2022.
- The 5-year median for Current Leases is $140500.0 (2023), against an average of $159937.5.
- The sharpest annual moves came in 2024 and 2025: Current Leases plunged 83.15% in 2024, then surged 890.32% in 2025.
- Trevi Therapeutics' Current Leases stood at $25000.0 in 2022, then soared by 636.0% to $184000.0 in 2023, then slumped by 83.15% to $31000.0 in 2024, then soared by 890.32% to $307000.0 in 2025, then rose by 3.58% to $318000.0 in 2026.
- Business Quant data shows TRVI's Current Leases at $318000.0 in Q1 2026, $307000.0 in Q4 2025, and $296000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Leases (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 720.00 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 11.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 16.75 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 21.95 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 45.93 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 6.27 Mn |
| 10 | Trevi Therapeutics | 2.71 Bn | 2.71 Bn | - | 329,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 329,000.00 |
| Mar 31, 2026 | 318,000.00 |
| Dec 31, 2025 | 307,000.00 |
| Sep 30, 2025 | 296,000.00 |
| Jun 30, 2025 | 286,000.00 |
| Mar 31, 2025 | 276,000.00 |
| Dec 31, 2024 | 254,000.00 |
| Sep 30, 2024 | 235,000.00 |
| Jun 30, 2024 | 216,000.00 |
| Mar 31, 2024 | 198,000.00 |
| Dec 31, 2023 | 184,000.00 |
| Sep 30, 2023 | 171,000.00 |
| Jun 30, 2023 | 157,000.00 |
| Mar 31, 2023 | 144,000.00 |
| Dec 31, 2022 | 25,000.00 |
| Sep 30, 2022 | 59,000.00 |
| Jun 30, 2022 | 92,000.00 |
| Mar 31, 2022 | 123,000.00 |
| Dec 31, 2021 | 120,000.00 |
| Sep 30, 2021 | 116,000.00 |